NewAmsterdam Pharma Company N.V. is a late-stage biopharmaceutical company focused on developing therapies for cardiometabolic diseases, particularly targeting patients with elevated low-density lipoprotein cholesterol (LDL-C) where existing treatments are inadequate. The company's primary product candidate, obicetrapib, is a CETP inhibitor designed to lower LDL-C as an adjunct to statin therapy.
Description via Wikipedia
Some research tools need a free Smallfolk account or a Smallfolk Pro plan.